Nuvalent (NASDAQ:NUVL) Downgraded by Truist Financial to “Hold”

Truist Financial downgraded shares of Nuvalent (NASDAQ:NUVL) from a strong-buy rating to a hold rating in a research report released on Tuesday,Zacks.com reports.

A number of other research analysts also recently issued reports on the stock. HC Wainwright downgraded shares of Nuvalent from a “buy” rating to a “neutral” rating and set a $124.00 price target on the stock. in a research report on Tuesday. Guggenheim downgraded shares of Nuvalent from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $151.00 to $124.00 in a research report on Wednesday. Canaccord Genuity Group downgraded shares of Nuvalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Raymond James Financial downgraded shares of Nuvalent from an “outperform” rating to a “market perform” rating in a research report on Tuesday. Finally, Wedbush downgraded shares of Nuvalent from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $125.00 to $124.00 in a research report on Tuesday. Five investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $131.15.

Nuvalent Price Performance

NASDAQ NUVL opened at $123.35 on Tuesday. The company’s fifty day moving average price is $103.44 and its two-hundred day moving average price is $103.19. Nuvalent has a 12 month low of $71.13 and a 12 month high of $123.62. The company has a market capitalization of $9.74 billion, a price-to-earnings ratio of -20.35 and a beta of 1.15.

Nuvalent (NASDAQ:NUVL) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.04). During the same period in the prior year, the company posted ($1.18) EPS. As a group, analysts anticipate that Nuvalent will post -5.74 EPS for the current year.

Insider Activity at Nuvalent

In other Nuvalent news, insider Henry E. Pelish sold 3,093 shares of the firm’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $104.48, for a total transaction of $323,156.64. Following the transaction, the insider owned 65,604 shares of the company’s stock, valued at approximately $6,854,305.92. This trade represents a 4.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Alexandra Balcom sold 11,430 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $105.21, for a total transaction of $1,202,550.30. Following the transaction, the chief financial officer directly owned 85,533 shares in the company, valued at approximately $8,998,926.93. The trade was a 11.79% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 126,953 shares of company stock worth $12,612,264 in the last 90 days. Corporate insiders own 5.02% of the company’s stock.

Hedge Funds Weigh In On Nuvalent

Large investors have recently bought and sold shares of the stock. GAMMA Investing LLC increased its stake in Nuvalent by 47.6% during the 4th quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock valued at $34,000 after buying an additional 108 shares during the period. EverSource Wealth Advisors LLC increased its stake in Nuvalent by 141.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock valued at $34,000 after buying an additional 195 shares during the period. Aster Capital Management DIFC Ltd acquired a new position in Nuvalent during the 3rd quarter valued at about $38,000. NBC Securities Inc. acquired a new position in shares of Nuvalent in the 4th quarter worth approximately $125,000. Finally, KBC Group NV grew its stake in shares of Nuvalent by 24.1% in the 4th quarter. KBC Group NV now owns 1,527 shares of the company’s stock worth $154,000 after purchasing an additional 297 shares during the last quarter. Institutional investors and hedge funds own 97.26% of the company’s stock.

Trending Headlines about Nuvalent

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK’s $10.6 billion all-cash acquisition offer gives Nuvalent shareholders a clear exit value at $124.00 per share, which is the biggest reason the stock has increased. Reuters article on GSK deal
• Positive Sentiment: Market commentary says the deal makes strategic sense for GSK because Nuvalent adds a late-stage oncology pipeline, supporting confidence that the transaction is credible and financially meaningful. MarketBeat analysis of the acquisition
• Neutral Sentiment: Several shareholder law firms have launched investigations into whether the sale process and price are fair, which could create headline noise but does not change the announced terms. Business Wire article on investigation
• Neutral Sentiment: Analyst downgrades followed the takeover news, but their revised price targets remain close to the deal value, so these moves are unlikely to outweigh the acquisition catalyst. Analyst downgrade coverage
• Negative Sentiment: CEO James Richard Porter sold 30,000 shares, a modest negative sentiment signal that may reinforce the view that insiders have been reducing exposure ahead of the transaction. SEC insider filing

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.